<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836990</url>
  </required_header>
  <id_info>
    <org_study_id>Prevena</org_study_id>
    <nct_id>NCT02836990</nct_id>
  </id_info>
  <brief_title>Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery</brief_title>
  <official_title>Prevena™ Incision Management System Versus Dermabond in the Prevention of Groin Wound Infections in Patients Undergoing Vascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical efficacy and cost effectiveness of Prevena Incision
      Management System versus Dermabond in preventing groin wound infections in patients who
      undergo vascular surgery requiring a groin wound. Half of the patients will receive Dermabond
      and the other half will receive the Prevena Incision Management System for their groin
      wounds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dermabond and the Prevena Incision Management System are both FDA approved wound care
      products. Prevena is a negative pressure system which holds the wound together and removes
      exudate and debris from the site to prevent infection. Dermabond is a surgical glue which
      holds the wound together to prevents infection. Prevena is more expensive to apply. However,
      the hypothesis is that the Prevena System will decrease infection rates and therefore,
      decrease the ultimate cost of the health care needed after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of healing of groin wounds between patients treated with Prevena vs Dermabond</measure>
    <time_frame>30 days</time_frame>
    <description>The primary effectiveness endpoint is 30 day healing of the randomized groin incision, with any wound infection or failure to heal. Szilagyi wound infection grade quantified on an ordinal scale will be used to assess the healing (None, Grade I: Infection contained to the dermis, Grade II: Infection extending into the subcutaneous tissue but the arterial graft is not involved, Grade III: Infection of the arterial graft or native vessel underlying the incision).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost of care</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of cost of treatment between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibiotic use upon discharge</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visiting nurses home visits and physician office visits to assess/treat wound infection</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>Prevena</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prevena Incision Management System for vascular surgical groin wounds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dermabond</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dermabond for vascular surgical groin wounds</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena Incision Management System</intervention_name>
    <description>A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections</description>
    <arm_group_label>Prevena</arm_group_label>
    <other_name>Prevena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermabond</intervention_name>
    <description>A surgical skin adhesive used to prevent surgical wound infections</description>
    <arm_group_label>Dermabond</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In need of elective vascular procedure requiring ≥8 cm groin incision.

          2. Able to provide consent

          3. Able to care for wound or have support person to complete wound care

          4. Willing to comply with follow-up

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Harris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda M Harris, MD</last_name>
    <phone>716-859-4225</phone>
    <email>lmharris@buffalo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alice Balk, BSN, RN</last_name>
    <phone>716-888-4764</phone>
    <email>alicebal@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaleida Health, Gates Vascular Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Harris, MD</last_name>
      <phone>716-859-4225</phone>
      <email>lmharris@buffalo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State University of New York at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Harris, MD</last_name>
      <phone>716-859-4225</phone>
      <email>lmharris@buffalo.edu</email>
    </contact>
    <investigator>
      <last_name>Maciej Dryjski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonya Noor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>G. Richard Curl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Cherr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Komornicki, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.woundsource.com/product/prevena-incision-management-system</url>
    <description>Prevena TM Incision Management System</description>
  </link>
  <reference>
    <citation>Ploeg AJ, Lardenoye JW, Peeters MP, Hamming JF, Breslau PJ. Wound complications at the groin after peripheral arterial surgery sparing the lymphatic tissue: a double-blind randomized clinical trial. Am J Surg. 2009 Jun;197(6):747-51. doi: 10.1016/j.amjsurg.2008.04.014. Epub 2008 Oct 17.</citation>
    <PMID>18929355</PMID>
  </reference>
  <reference>
    <citation>Lee ES, Santilli SM, Olson MM, Kuskowski MA, Lee JT. Wound infection after infrainguinal bypass operations: multivariate analysis of putative risk factors. Surg Infect (Larchmt). 2000 Winter;1(4):257-63.</citation>
    <PMID>12594881</PMID>
  </reference>
  <reference>
    <citation>Lawlor DK, Derose G, Harris KA, Lovell MB, Novick TV, Forbes TL. The role of platelet-rich plasma in inguinal wound healing in vascular surgery patients. Vasc Endovascular Surg. 2011 Apr;45(3):241-5. doi: 10.1177/1538574411399157.</citation>
    <PMID>21478245</PMID>
  </reference>
  <reference>
    <citation>Exton RJ, Galland RB. Major groin complications following the use of synthetic grafts. Eur J Vasc Endovasc Surg. 2007 Aug;34(2):188-90. Epub 2007 May 18.</citation>
    <PMID>17512763</PMID>
  </reference>
  <reference>
    <citation>Engin C, Posacioglu H, Ayik F, Apaydin AZ. Management of vascular infection in the groin. Tex Heart Inst J. 2005;32(4):529-34.</citation>
    <PMID>16429897</PMID>
  </reference>
  <reference>
    <citation>Bandyk DF. Vascular surgical site infection: risk factors and preventive measures. Semin Vasc Surg. 2008 Sep;21(3):119-23. doi: 10.1053/j.semvascsurg.2008.05.008. Review.</citation>
    <PMID>18774446</PMID>
  </reference>
  <reference>
    <citation>Swinnen J, Chao A, Tiwari A, Crozier J, Vicaretti M, Fletcher J. Vertical or transverse incisions for access to the femoral artery: a randomized control study. Ann Vasc Surg. 2010 Apr;24(3):336-41. doi: 10.1016/j.avsg.2009.07.020. Epub 2009 Dec 4.</citation>
    <PMID>19962270</PMID>
  </reference>
  <reference>
    <citation>Dosluoglu HH, Loghmanee C, Lall P, Cherr GS, Harris LM, Dryjski ML. Management of early (&lt;30 day) vascular groin infections using vacuum-assisted closure alone without muscle flap coverage in a consecutive patient series. J Vasc Surg. 2010 May;51(5):1160-6. doi: 10.1016/j.jvs.2009.11.053. Epub 2010 Mar 31.</citation>
    <PMID>20356703</PMID>
  </reference>
  <reference>
    <citation>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78; quiz 279-80.</citation>
    <PMID>10219875</PMID>
  </reference>
  <reference>
    <citation>Easterlin B, Bromberg W, Linscott J. ﻿A Novel Technique of Vacuum-assisted Wound Closure That Functions as a Delayed Primary Closure. Wounds. 2007 Dec;19(12):331-3.</citation>
    <PMID>25942681</PMID>
  </reference>
  <reference>
    <citation>de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control. 2009 Jun;37(5):387-97. doi: 10.1016/j.ajic.2008.12.010. Epub 2009 Apr 23.</citation>
    <PMID>19398246</PMID>
  </reference>
  <reference>
    <citation>Weir G. The use of a surgical incision management system on vascular surgery incisions: a pilot study. Int Wound J. 2014 Jun;11 Suppl 1:10-2. doi: 10.1111/iwj.12261.</citation>
    <PMID>24851730</PMID>
  </reference>
  <reference>
    <citation>Matatov T, Reddy KN, Doucet LD, Zhao CX, Zhang WW. Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. J Vasc Surg. 2013 Mar;57(3):791-5. doi: 10.1016/j.jvs.2012.09.037. Epub 2013 Jan 9.</citation>
    <PMID>23312938</PMID>
  </reference>
  <reference>
    <citation>Bruns TB, Worthington JM. Using tissue adhesive for wound repair: a practical guide to dermabond. Am Fam Physician. 2000 Mar 1;61(5):1383-8. Review.</citation>
    <PMID>10735344</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Linda Harris</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

